Turkish League Against Rheumatism National recommendations for the management of ankylosing spondylitis;Türkiye romatizma araştırma ve savaş derneǧi ankilozan spondilit ulusal tedavi önerileri

Turkish Journal of Rheumatology

Volumn 26, Issue 3, 2011, Pages 173-186

  Bodur, Hatice ^a   Sivas, Filiz ^a   Yilmaz, Özlem ^a   Özgöçmen, Salih ^b   Günaydin, Rezzan ^c   Kaya, Taciser ^c   Ataman, Şebnem ^d   Altan, Lale ^e   Altay, Zuhal ^f   Aydoǧ, Ece ^g   Birtane, Murat ^h   Borman, Pinar ^a   Buǧdayci, Derya Soy ⁱ   Bütün, Bülent ^j   Çakirbay, Haşim ^k   Duruöz, Tuncay ^l   Gürer, Gülcan ^m   Hepgüler, Simin ⁿ   Kamanli, Ayhan ^o   Kuru, Ömer ^p   Küçükdeveci, Ayşe ^d   Nacir, Bariş ^a   Ölmez, Neşe ^q   Rezvani, Aylin ^r   Yanik, Burcu Çörekçi ^k   more..

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c Klinik FTR   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e ULUDAG UNIVERSITY   (Turkey)

^f INONU UNIVERSITY   (Turkey)

^g YEDITEPE UNIVERSITY   (Turkey)

^h TRAKYA UNIVERSITY   (Turkey)

ⁱ Istanbul Physical Medicine and Rehabilitation Training and Research Hospital   (Turkey)

^j AKDENIZ UNIVERSITY   (Turkey)

^k FATIH UNIVERSITY   (Turkey)

^l CELAL BAYAR UNIVERSITY   (Turkey)

^m Van Devlet Hastanesi   (Turkey)

ⁿ EGE UNIVERSITY   (Turkey)

^o FIRAT UNIVERSITY   (Turkey)

^p ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^q ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^r BEZMIALEM VAKIF UNIVERSITY   (Turkey)

more..

Author keywords

Ankylosing spondylitis; National recommendations; Treatment

Indexed keywords

ADALIMUMAB; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRITIS; BALNEOTHERAPY; CARDIOTOXICITY; CHRONIC PAIN; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EVIDENCE BASED MEDICINE; FIBROMYALGIA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIP ARTHROPLASTY; HUMAN; JOINT STIFFNESS; KINESIOTHERAPY; MUSCLE STIFFNESS; NAUSEA; NEUROPATHIC PAIN; OSTEOPENIA; OSTEOPOROSIS; PAIN; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PHANTOM PAIN; PROCESS DEVELOPMENT; RATING SCALE; REVIEW; RHEUMATOID ARTHRITIS; SPINAL PAIN; SPINE SURGERY; SYSTEMATIC REVIEW; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT RESPONSE; TURKEY (REPUBLIC); UVEITIS; VERTEBRA FRACTURE; VOMITING;

EID: 80053229571     PISSN: 13090291     EISSN: 13090283     Source Type: Journal    
DOI: 10.5152/tjr.2011.028     Document Type: Review

References (66)

1. Onen F, Akar S, Birlik M, Sari I, Khan MA, Gurler O, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008;35:305-309.
2. Bodur H, Ataman S, Buǧdayci DS, Rezvani A, Nas K, Uzunca K, et al. Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP. Rheumatol Int 2010. [Epub ahead of print]
3. Bodur H, Ataman S, Rezvani A, Buǧdayci DS, Cevik R, Birtane M, et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011;20:543-54.
4. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-432.
5. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452.
6. Kiltz U, van der Heijde D, Mielants H, Feldtkeller E, Braun J; PARE/EULAR patient initiative group. ASAS/ EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis 2009;68:1381-1386.
7. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
8. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann 7Rheum Dis 2004;63:1172-1176.
9. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991;44:1271-1278.
10. Sidiropoulos PI, Hatemi G, Song IH, Avouac J, Collantes E, Hamuryudan V, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 2008;47:355-361.
11. Stone MA, Pomeroy E, Keat A, Sengupta R, Hickey S, Dieppe P, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology (Oxford) 2008;47:1213-1218.
12. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:1276-12781.
13. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL; BSR Biologics Register. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010;49:563-570.
14. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-808.
15. Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009;48:1029-1035.
16. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-2451.
17. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-1634.
18. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-647.
19. Magrey M, Khan MA. Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep 2010;12:332-336.
20. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:175-182.
21. Zeidler H, Amor B. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 2011;70:1-3.
22. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 8 Suppl 2:ii1-ii44.
23. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
24. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-1818.
25. Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065-10671.
26. Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2009;21:324-334.
27. Vliet Vlieland TP, Li LC. Rehabilitation in rheumatoid arthritis and ankylosing spondylitis: differences and similarities. Clin Exp Rheumatol 2009;27:S171-S178.
28. Barlow JH, Barefoot J. Group education for people with arthritis. Patient Educ Couns 1996;27:257-267.
29. Krauth C, Rieger J, Bönisch A, Ehlebracht-König I. Costs and benefits of an education program for patients with ankylosing spondylitis as part of an inpatient rehabilitation programs-study design and first results. Z Rheumatol 2003;62:II14-II16. [Abstract]
30. Foster G, Taylor SJ, Eldridge SE, Ramsay J, Griffiths CJ. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane Database Syst Rev 2007;CD005108.
31. Kaya T, Atici Öztürk P, Göksel Karatepe A, Günaydin R. Impact of peer-led education on quality of life and knowledge about disease in patients with ankylosing spondylitis. Rheumatology 2011;50(Suppl 2):ii2. 32.
32. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;CD002822.
33. Durmuş D, Alayli G, Uzun O, Tander B, Cantürk F, Bek Y, et al. Effects of two exercise interventions on pulmonary functions in the patients with ankylosing spondylitis. Joint Bone Spine 2009;76:150-155.
34. Karapolat H, Eyigor S, Zoghi M, Akkoc Y, Kirazli Y, Keser G. Are swimming or aerobic exercise better than conventional exercise in ankylosing spondylitis patients? A randomized controlled study. Eur J Phys Rehabil Med 2009;45:449-4457.
35. Widberg K, Karimi H, Hafström I. Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis-a randomized study. Clin Rehabil 2009;23:599-608.
36. Yurtkuran M, Ay A, Karakoç Y. Improvement of the clinical outcome in Ankylosing spondylitis by balneotherapy. Joint Bone Spine 2005;72:303-308.
37. Altan L, Bingöl U, Aslan M, Yurtkuran M. The effect of balneotherapy on patients with ankylosing spondylitis. Scand J Rheumatol 2006;35:283-289.
38. Falagas ME, Zarkadoulia E, Rafailidis PI. The therapeutic effect of balneotherapy: evaluation of the evidence from randomised controlled trials. Int J Clin Pract 2009;63:1068-1084.
39. Oosterveld FG, Rasker JJ, Floors M, Landkroon R, van Rennes B, Zwijnenberg J, et al. Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. A pilot study showing good tolerance, short-term improvement of pain and stiffness, and a trend towards long-term beneficial effects. Clin Rheumatol 2009;28:29-34.
40. Gurcay E, Yuzer S, Eksioglu E, Bal A, Cakci A. Stanger bath therapy for ankylosing spondylitis: illusion or reality? Clin Rheumatol 2008;27:913-917.
41. Spadaro A, De Luca T, Massimiani MP, Ceccarelli F, Riccieri V, Valesini G. Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. Joint Bone Spine 2008;75:29-33.
42. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008;58:929-938.
43. Sieper J. Can structural damage be prevented in ankylosing spondylitis? Curr Opin Rheumatol 2009;21:335-339.
44. Poddubnyy D, Song IH, Sieper J. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: nonsteroidal anti-inflammatory drugs. Clin Exp Rheumatol 2009;27:S148-S151.
45. Wanders A, Heijde D, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-1765.
46. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-1594.
47. Spies CM, Burmester GR, Buttgereit F. Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis-a systematic comparison. Clin Exp Rheumatol 2009;27:S152-S158.
48. Haibel H, Specker C. Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:S159-S163.
49. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;CD004800.
50. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006;65:1147-1153.
51. Kabasakal Y, Kitapcioglu G, Yargucu F, Taylan A, Argin M, Gumusdis G. Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS. Rheumatol Int 2009;29:1523-1527.
52. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 2000;340-343.
53. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007; 66:419-421.
54. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005;64:124-126.
55. Goh L, Samanta A. A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 2009;29:1123-1135.
56. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-345.
57. Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine 2010;77:325-329.
58. Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-352.
59. Martín-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:238-245.
60. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2006;54:2136-2146.
61. van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009;11:R124.
62. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-908.
63. Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009;36:1421-1428.
64. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011;70 Suppl 1:i2-i36.
65. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:335-339.
66. Bradley WG Jr. Low back pain. AJNR Am J Neuroradiol 2007;28:990-992.